Literature DB >> 19825531

[Decision process in oncology: the importance of multidisciplinary meeting].

M-B Orgerie1, N Duchange, N Pélicier, S Chapet, E Dorval, P Rosset, E Lemarié, C Hervé, G Moutel.   

Abstract

Multidisciplinary meeting (MDM) in oncology has been institutionalised in France by the Cancer Plan. This study aims to determine the place of MDM in the decision process. From November 2004 to July 2005, we observed 29 meetings at the Tours Hospital and 324 case presentations, 80 in orthopaedics, 151 in gastroenterology and 93 in chest medicine. Forty physicians attending the meetings answered a questionnaire exploring their opinions on MDM and the collegial decision. We found that MDM is mostly the place for technical discussions and that patients' wishes are rarely addressed. The different medical specialities are well represented but we observed that only physicians attend MDM. Decisions for straightforward cases are rapidly validated. For more complex clinical situations (25 to 40% of case presentations), the multidisciplinary approach allows to adapt guidelines or to choose alternative treatments. All the physicians interviewed express that MDM legitimates the medical decision. It occurs that they disagree with the RCP decision. We discuss how MDM impacts on the medical decision as well as the shift from the individual decision to the collective one, particularly in term of responsibility.

Entities:  

Mesh:

Year:  2010        PMID: 19825531     DOI: 10.1684/bdc.2009.0957

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  Multidisciplinary team meeting in digestive oncology: when opinions differ.

Authors:  Alban Zarzavadjian Le Bian; Renato Costi; Audrey Bruderer; Christian Herve; Claude Smadja
Journal:  Clin Transl Sci       Date:  2014-05-19       Impact factor: 4.689

2.  Patients' Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings.

Authors:  Léa Restivo; Thémis Apostolidis; Anne-Déborah Bouhnik; Sylvain Garciaz; Thérèse Aurran; Claire Julian-Reynier
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.